Everest Medicines a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital.

珠穆朗玛峰药物（Everest Medicines）是一家专注于创新疗法的发现，临床开发，制造和商业化的生物制药公司，今天宣布在北京大学癌症医院和复旦大学癌症医院进行EVM16CX01研究，启动研究者发起的个性化mRNA癌症疫苗EVM16临床试验（IIT）。

This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. EVM16CX01 is the first-in-human (FIH) trial for EVM16.EVM16 is a novel personalized therapeutic mRNA cancer vaccine independently developed by Everest.

该试验旨在评估EVM16注射液作为单一疗法以及与PD-1抗体联合用于晚期或复发性实体瘤患者的安全性，耐受性，免疫原性和初步疗效。EVM16CX01是EVM16的首次人体试验（FIH）。EVM16是由Everest独立开发的新型个性化治疗性mRNA癌症疫苗。

EVM16 contains neoantigens with high immunogenicity potential that are predicted based on the unique tumor mutations of each patient by Everest’s proprietary neoantigen prediction algorithm. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.'EVM16 is the first personalized mRNA cancer vaccine independently developed by Everest using our proprietary mRNA platform.

EVM16含有具有高免疫原性潜力的新抗原，这些新抗原是根据Everest专有的新抗原预测算法根据每位患者的独特肿瘤突变预测的。该疫苗使用脂质纳米颗粒（LNP）递送系统在体内有效递送新抗原编码的mRNA，激活新抗原特异性肿瘤杀伤T细胞并抑制肿瘤生长EVM16是Everest使用我们专有的mRNA平台独立开发的第一种个性化mRNA癌症疫苗。

The initiation of this clinical trial is an important milestone that demonstrates our commitment to discover and develop a new generation of mRNA immunotherapies for cancer and autoimmune diseases.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.“While establishing leadership positions in nephrology, infectious disease, and autoimmune diseases, Everest will also focus on innovative modalities such as therapeutic mRNA vaccines.

这项临床试验的启动是一个重要的里程碑，表明我们致力于发现和开发针对癌症和自身免疫性疾病的新一代mRNA免疫疗法。”珠穆朗玛峰医药首席执行官罗杰斯·永清（Rogers Yongqing Luo）表示。“珠穆朗玛峰在肾脏病、传染病和自身免疫性疾病领域确立领导地位的同时，还将专注于创新模式，如治疗性mRNA疫苗。

We look forward to seeing personalized cancer vaccines become .

我们期待着看到个性化的癌症疫苗成为。